Skip to main content

Jounce Therapeutics, Inc.

JNCEDelisted May 4, 2023
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001640455

Jounce Therapeutics, Inc. was delisted on May 4, 2023; its insiders filed their last Form 4 on May 5, 2023; 84 institutions reported holding it in 13F filings for Q1 2023, worth $64.1M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Jounce Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Jounce Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Jounce Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Tang Kevin CDirector, 10% Owner10,000IndirectMay 5, 20230
Tang Capital Partners LP10% Owner10,000IndirectMay 5, 20230
Tang Capital Management LLC10% Owner10,000IndirectMay 5, 20230
Concentra Biosciences, LLC10% Owner10,000May 5, 20230
Murray RichardDirector1May 4, 20230
Karsen Perry ADirector0May 4, 20230
Drapkin Kimberlee CPresident, CFO and Treasurer0May 4, 20230
Duncan Barbara GayleDirector–May 4, 20230
Kamen RobertDirector0IndirectMay 4, 20230
Diaz LuisDirector–May 4, 20230
Iannone RobertDirector–May 4, 20230
Raythatha JigarDirector–May 4, 20230
Salter-Cid LuisaDirector–May 4, 20230
Cole Hugh MChief Operating Officer110,082Jan 11, 20230
Trehu ElizabethChief Medical Officer103,417Jan 11, 20230
Higgons John DuncanDirector–Jun 28, 20220
Levin Mark J10% Owner1,148,780Nov 16, 20210
Tepper Robert I10% Owner1,148,780Nov 16, 20210
Starr Kevin P10% Owner1,148,780Nov 16, 20210
Third Rock Ventures III, L.P.10% Owner1,148,780Nov 16, 20210
TRV GP III, LLC10% Owner1,148,780Nov 16, 20210
Third Rock Ventures GP III, L.P.10% Owner1,148,780Nov 16, 20210
Pfeffer CaryDirector0IndirectNov 16, 20210
Third Rock Ventures II, L.P.10% Owner2,697,829Sep 17, 20210
Third Rock Ventures GP II, L.P.10% Owner2,697,829Sep 17, 20210
TRV GP II, LLC10% Owner2,697,829Sep 17, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 6, 2023 (view filing)Apr 42 daysMurray RichardDirectorSSale−39.2K$1.85−$72.6K−17.2%188.8K after10b5-1
Mar 14, 2023 (view filing)8:39 PM ETMar 13-141 dayTang Kevin C and 2 others10% OwnerPPurchase+86.0K$0.9997+$86.0K+1.6%5.30M after2 lots
Jan 11, 2023 (view filing)Jan 9-102 daysTrehu ElizabethChief Medical OfficerSSale−9.29K$1.11−$10.3K−8.2%103.4K after2 lots
Jan 11, 2023 (view filing)Jan 9-102 daysMurray RichardCEO and PresidentSSale−45.1K$1.11−$50.1K−16.5%228.0K after2 lots
Jan 11, 2023 (view filing)Jan 9-102 daysDrapkin Kimberlee CCFO and TreasurerSSale−14.1K$1.11−$15.7K−17.6%66.0K after2 lots
Jan 11, 2023 (view filing)Jan 9-102 daysCole Hugh MChief Operating OfficerSSale−16.6K$1.11−$18.5K−13.1%110.1K after2 lots
Jan 11, 2022 (view filing)Jan 7-104 daysTrehu ElizabethChief Medical OfficerSSale−8.38K$6.88−$57.7K−9.0%85.2K after2 lots
Jan 11, 2022 (view filing)Jan 7-104 daysMurray RichardCEO and PresidentSSale−37.3K$6.88−$256.7K−16.7%185.6K after2 lots
Jan 11, 2022 (view filing)Jan 7-104 daysDrapkin Kimberlee CCFO and TreasurerSSale−12.8K$6.88−$88.2K−19.6%52.6K after2 lots
Jan 11, 2022 (view filing)Jan 7-104 daysCole Hugh MChief Business OfficerSSale−9.67K$6.88−$66.6K−13.1%64.2K after2 lots
Nov 16, 2021 (view filing)7:57 PM ETNov 124 daysLevin Mark J and 5 others10% OwnerSSale−1.90M$8.38−$15.9M−62.3%1.15M after
Nov 16, 2021 (view filing)Nov 124 daysPfeffer CaryDirectorSSale0–$0–0 after